Clinically, cancer is characterized by the uncontrollable division of cells, which can multiply and spread, making the condition life-threatening. Treatment strategies have evolved significantly, with ...

Promising therapies for platinum-resistant ovarian cancer produced mixed results in separate trials. The AKT inhibitor ...

This drug blocks a protein called mTOR, which helps cancer cells grow ... stops the checkpoint protein PD-1 from attaching to another protein, PD-L1, that sits on the surface of T cells.

We further investigated the relationship between clustering and PD-L1 or CTLA-4. The two immune checkpoint proteins ... and differentiation but may possibly be sensitive to PI3K/AKT/mTOR signaling ...

The following is a summary of “Efficacy and safety of PD-1/PD-L1 inhibitor monotherapy or combination therapy versus platinum-based chemotherapy as a first-line treatment of advanced urothelial cancer ...

Jiangsu Hengrui Pharmaceuticals and its partner Elevar Therapeutics will have to wait even longer before their PD-1 inhibitor ...

Technologies announced its PD-L1 IHC 28-8 pharmDx kit has received two new companion diagnostic indications approvals under EU ...

Journal of the American Medical Association study provides further evidence that Multikine can treat unmet need in ~70% of ...

A  team of researchers from Cleveland Clinic share insights from an early set of 19,000 patients to receive immune checkpoint inhibitor treatments for colorectal cancer in the US.   The report comes ...